Efficacy and Durability of Exenatide in Combination with Pioglitazone vs. Basal-Bolus Insulin in Poorly Controlled Type 2 Diabetic Patients: The QATAR Study

被引：0
|
作者：
Abdul-Ghani, Muhammad
Mujahed, Osama
Mujahed, Ayman
Hassoun, Shai-Maa
Alkasem, Meis
Abou Samra, Abdel Badi
Zirie, Mahmoud
Defronzo, Ralph A.
Jayyousi, Amin
机构：
来源：
DIABETES | 2016年 / 65卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
188-OR
引用
收藏
页码：A49 / A49
页数：1
相关论文
共 50 条
  • [1] The efficacy and durability of exenatide in combination with pioglitazone versus basal bolus insulin in poorly controlled type 2 diabetic patients: the QATAR study
    Abdul-Ghani, M.
    Migahid, O.
    Migahid, A.
    Hassoun, S.
    Alkasem, M.
    Zirie, M.
    DeFronzo, R. A.
    Jayyousi, A.
    DIABETOLOGIA, 2016, 59 : S379 - S379
  • [2] Effect of treatment with exenatide and pioglitazone or basal-bolus insulin on diabetic neuropathy: a substudy of the Qatar Study
    Ponirakis, Georgios
    Abdul-Ghani, Muhammad A.
    Jayyousi, Amin
    Almuhannadi, Hamad
    Petropoulos, Ioannis N.
    Khan, Adnan
    Gad, Hoda
    Migahid, Osama
    Megahed, Ayman
    DeFronzo, Ralph
    Mahfoud, Ziyad
    Hassan, Mona
    Al Hamad, Hanadi
    Ramadan, Marwan
    Alam, Uazman
    Malik, Rayaz A.
    BMJ OPEN DIABETES RESEARCH & CARE, 2020, 8 (01)
  • [3] Durability of Combination Therapy with Exenatide and Pioglitazone vs. Basal Bolus Insulin in Poorly Controlled T2DM Patients-Three-Year Follow-Up of the QATAR Study
    Abdul-Ghani, Muhammad
    Migahid, Osama, Sr.
    Megahed, Ayman, Sr.
    Mohammad, Mohammad Fawaz.
    Defronzo, Ralph A.
    Jayyousi, Amin
    DIABETES, 2018, 67
  • [4] Combination Therapy With Exenatide Plus Pioglitazone Versus Basal/Bolus Insulin in Patients With Poorly Controlled Type 2 Diabetes on Sulfonylurea Plus Metformin: The Qatar Study
    Abdul-Ghani, Muhammad
    Migahid, Osama
    Megahed, Ayman
    Adams, John
    Triplitt, Curtis
    DeFronzo, Ralph A.
    Zirie, Mahmoud
    Jayyousi, Amin
    DIABETES CARE, 2017, 40 (03) : 325 - 331
  • [5] Combination Therapy With Exenatide Plus Pioglitazone Versus Basal/Bolus Insulin in Patients With Poorly Controlled Type 2 Diabetes on Sulfonylurea Plus Metformin: The Qatar Study (vol 40, pg 325, 2017)
    Abdul-Ghani, Muhammad
    Migahid, Osama
    Megahed, Ayman
    Adams, John
    Triplitt, Curtis
    DeFronzo, Ralph A.
    Zirie, Mahmoud
    Jayyousi, Amin
    DIABETES CARE, 2017, 40 (08) : 1134 - 1134
  • [6] Insulin secretion predicts the response to therapy with exenatide plus pioglitazone, but not to basal/bolus insulin in poorly controlled T2DM patients: Results from the Qatar study
    Abdul-Ghani, Muhammad
    Migahid, Osama
    Megahed, Ayman
    Singh, Rajvir
    Kamal, Dalia
    DeFronzo, Ralph A.
    Jayyousi, Amin
    DIABETES OBESITY & METABOLISM, 2018, 20 (04): : 1075 - 1079
  • [7] EFFICACY OF THE DIABEO SYSTEM FOR THE PRAGMATIC TELEMEDICINE MANAGEMENT OF DIABETIC PATIENTS POORLY CONTROLLED WITH A BASAL-BOLUS INSULIN REGIMEN
    Franc, S.
    Hanaire, H.
    Benhamou, P. -Y.
    Schaepelynck, P.
    Catargi, B. C.
    Farret, A.
    Fontaine, P.
    Guerci, B.
    Reznik, Y.
    Jeandidier, N.
    Penfornis, A.
    Borot, S.
    Chaillous, L.
    Serusclat, P.
    Kherbachi, Y.
    D'Orsay, G.
    Detournay, B.
    Simon, P.
    Charpentier, G.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2020, 22 : A152 - A153
  • [8] Corneal confocal microscopy shows nerve regeneration after treatment with exenatide/pioglitazone or basal/bolus insulin in patients with poorly controlled type 2 diabetes
    Malik, R.
    Ponirakis, G.
    Khan, A.
    Al-Muhannadi, H.
    Petropoulos, I.
    Migahid, O.
    Jayyousi, A.
    Abdul-Ghani, M.
    DIABETOLOGIA, 2018, 61 : S130 - S130
  • [9] "SURPASS(ing)" an Era of Basal-Bolus Insulin Therapy-Tirzepatide vs. Insulin Lispro TID Added-on to Poorly Controlled Basal Insulin-Treated in Type 2 Diabetes
    Rosenstock, Julio
    Frias, Juan P.
    Rodbard, Helena W.
    Tofe, Santiago
    Sears, Emmalee J.
    Huh, Ruth
    Lando, Laura Fernandez
    Patel, Hiren
    DIABETES, 2023, 72
  • [10] USE OF BASAL INSULIN-GLP1 COMBINATION FOR THERAPEUTIC SIMPLIFICATION IN TYPE 2 DIABETIC PATIENTS WITH A BASAL-BOLUS OR BASAL PLUS SCHEME
    Jaramillo-Nieto, A.
    Gomez Hernandez, I.
    Tique, C.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2022, 24 : A180 - A180
12345